Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | HMGCR | P04035 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.33 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.33 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium Ion SCHEMBL11895562 | 0.88 | ALOX5 (0.36) | ALOX5SMN1; SMN2ALDH1A1PKMCYP3A4 | |
| SCHEMBL1044434 | 0.88 | HMGCR (0.49) | ALOX5HMGCRPOLBMAPTHDAC3 | |
| SCHEMBL1078625 | 0.83 | HPGD (0.37) | ALOX5HMGCRSMN1; SMN2LMNAPOLB | |
| Potassium Ion SCHEMBL1077762 | 0.80 | FABP3 (0.39) | ALOX5HMGCRFABP3 | |
| Potassium Ion SCHEMBL1077457 | 0.80 | FABP3 (0.39) | ALOX5HMGCRFABP3 | |
| Potassium Ion SCHEMBL2581887 | 0.80 | FABP3 (0.39) | ALOX5HMGCRFABP3 | |
| SCHEMBL8863670 | 0.77 | PTPN7 (0.44) | ALOX5HMGCRLMNAPOLBMAPT | |
| Potassium SCHEMBL2593640 | 0.77 | KCNH2 (0.42) | ALOX5HMGCRPTPN7ALDH1A1CYP3A4 | |
| SCHEMBL11911412 | 0.72 | ALOX5 (0.42) | ALOX5SMN1; SMN2POLBPTPN7ALDH1A1 | |
| SCHEMBL5517928 | 0.70 | ALOX5 (0.44) | ALOX5LMNAPOLBMAPTCTDSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722910-B2 | Diyne compositions | EVOLVA AG (CH) | 2014-05-13 | — | — | US | claimed |
| EP-2563769-A1 | DIYNE COMPOSITIONS | EVOLVA AG (CH) | 2013-03-06 | — | — | EP | claimed |
| US-20120196822-A1 | Diyne Compositions | EVOLVA AG (CH) | 2012-08-02 | — | — | US | claimed |
| WO-2011134538-A1 | DIYNE COMPOSITIONS | EVOLVA LTD (CH) | 2011-11-03 | — | — | WO | claimed |
| US-8722910-B2 | Diyne compositions | EVOLVA AG (CH) | 2014-05-13 | — | — | US | disclosed |
| EP-2563769-A1 | DIYNE COMPOSITIONS | EVOLVA AG (CH) | 2013-03-06 | — | — | EP | disclosed |
| US-20120196822-A1 | Diyne Compositions | EVOLVA AG (CH) | 2012-08-02 | — | — | US | disclosed |
| WO-2011134538-A1 | DIYNE COMPOSITIONS | EVOLVA LTD (CH) | 2011-11-03 | — | — | WO | disclosed |
| WO-2011006061-A1 | DIYNE COMPOSITIONS | EVOLVA SA (CH) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196822-A1 | Diyne Compositions | OSR1, ERG28, OSBPL3 | ALOX5 845/4885HMGCR 2007/4885SMN1; SMN2 4269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.